Purpose: We aimed: (1) to establish endothelial expression of ubiquitin carboxyl-terminal esterase L1 (UCHL1) in human choroid and retina and; (2) to investigate a role for UCHL1 in basic processes involved in intraocular neovascularization.
I ntraocular neovascularization is directly responsible for loss of vision in age-related macular degeneration and diabetic retinopathy. These diseases are causes of substantial vision impairment and loss worldwide, particularly in high-income regions. 1 A major advance in the treatment of eye diseases characterized by ocular neovascularization has come in the last decade in the form of pharmacological inhibition of vascular endothelial growth factor (VEGF-A), which is a master regulator of vascularization. Vascular endothelial growth factor blockade, which may be achieved by RNA aptamer, soluble receptor, specific antibody or antibody fragment, and delivered directly to the eye by intraocular injection. Regresses intraocular neovascularization and significantly improves vision in patients with age-related macular degeneration in particular. 2, 3 However, the potential for toxicity to choroid and retina has stimulated interest in therapeutic targeting of alternative regulators of ocular neovascularization. 4 Ubiquitin carboxyl-terminal esterase L1 (UCHL1), which is also known as protein gene product 9.5, is a deubiquitinating enzyme that was identified 30 years ago as a ''brain-specific protein.'' 5 Indeed, UCHL1 is estimated to account for up to 2% of human brain soluble protein. 6 Ubiquitin carboxylterminal esterase L1 is present in peripheral and central nervous system neurons, including retinal ganglion and horizontal cells, where it is essential for axonal transport. 7, 8 Expression is repressed in nonneuronal cells by repressor element 1 silencing transcript factor, which binds neuron-restrictive silencer element. 7 Ubiquitin carboxyl-terminal esterase L1 has had much attention in the pathology literature as an immunohistochemical neuronal marker, and separately, in the neurological literature as a mediator of neurodegenerative disease. 7, 9 A handful of reports, including our own, 10Y13 have identified UCHL1 in endothelial subpopulations, but functional studies are yet to be published.
Our previous profiling studies identified UCHL1 transcript and protein in choroidal and retinal endothelial cells isolated from human eyes. 12, 13 Work from the field of oncological science indicated that UCHL1 might prevent hypoxia-inducible factor (HIF) 1> degradation. 14 Hypoxia-inducible factor 1 is a transcription factor that is activated when oxygen is scarce. The HIF-1 heterodimer consists of oxygen-sensitive HIF-1> and constitutively expressed HIF-1A subunits. In normoxia, HIF1-a is targeted for degradation via E3 von Hippel-Lindau tumor suppressor protein (VHL)-chaperoned ubiquitination. Hypoxia permits HIF1-a and HIF1-b dimerization, generating active HIF-1, which is a principal regulator of VEGF-A gene expression. This suggested to us the possibility that endothelial UCHL1 might influence intraocular neovascularization. After verifying the endothelial expression of UCHL1 in whole human choroid and retina, we investigated the involvement of UCHL1 in human choroidal and retinal endothelial proliferation and migration, which are key processes in blood vessel growth. 15 
MATERIALS AND METHODS

Immunohistochemistry
Choroid and retina were dissected from human cadaveric eyes (Lions VisionGift, Portland, Ore; n = 3), which were fixed in graded ethanol solutions and embedded in paraffin. Tissue cross sections were cut 5 Km in thickness, deparaffinized in xylene, and rehydrated through graded ethanol solutions. The sections were boiled in a microwave for 10 minutes in 10-mM citrate buffer at pH 6.0. After cooling, they were washed in a buffer of 50-mM Tris and 0.15-M sodium chloride at pH 7.5 (tris-buffered saline [TBS]). Nonspecific binding was blocked for 1 hour with a solution of TBS, 0.1% bovine serum albumin, 0.3% Triton X-100, and 2% vol/vol normal goat serum. The sections were incubated overnight at 4-C with a rabbit polyclonal antihuman UCHL1 antibody (Cedarlane Laboratories, Burlington, NC) or as a negative control, rabbit serum (Vector Laboratories, Burlingame, Calif ), which were both diluted in a ratio of 1:5000 in a blocking solution, and subsequently, they were washed with TBS. They were incubated with biotinylated goat antirabbit immunoglobulin (Vector Laboratories), which was diluted in a ratio of 1:200 in a blocking solution for 45 minutes, washed with TBS, and finally treated with streptavidinbiotin complex conjugated to alkaline phosphatase (Vector Laboratories). To visualize antibody complexes, the sections were incubated with Fast Red (BioGenex, San Ramon, Calif ), as described by the supplier.
Human Ocular Endothelial Cells
Choroidal or retinal endothelial cells were obtained from nondiseased eye pairs of 8 human cadaveric donors (Lions VisionGift), adhering closely to our previously published method. 16 In brief, choroid or retina was dissected from posterior eyecups and digested with graded solutions of Dispase (Gibco; Life Technologies, Carlsbad, Calif ) and type II collagenase (Sigma-Aldrich, St Louis, Mo) in MCDB-131 medium (Sigma-Aldrich) with 2% fetal bovine serum (FBS). The endothelial cells were isolated from the digested tissue using magnetic Dynabeads (Dynal; Invitrogen, Oslo, Norway) coated with mouse monoclonal antihuman CD31 antibody (BD Pharmingen, San Diego, Calif ), as per the manufacturer's instructions. The cells were cultured at 37-C and 3.5% to 5% CO 2 in MCDB-131 medium (Sigma-Aldrich) with up to 10% FBS and EGM-2 SingleQuots supplement, omitting gentamicin, hydrocortisone, and FBS (Clonetics; Lonza, Walkersville, Md). To generate sufficient cells for the study, the cells were transduced with the mouse recombinant amphotropic retrovirus, LXSN16E6E7 (gift of Denise A. Galloway, PhD, of Fred Hutchinson Cancer Institute).
Small Interfering RNA Blockade
Ubiquitin carboxyl-terminal esterase L1Ytargeted small interfering RNA (siRNA) were designed using siDirect 17 and synthesized by Life Technologies-Invitrogen: sense, 5 ¶-GAAGUUAG UCCUAAAGUGUAC-3 ¶; and antisense, 5 ¶-ACACUUUAGGAC UAACUUCUU-3 ¶. Control siRNA was designed by scrambling the constituent nucleotides to generate nontargeted sequence: sense, 5 ¶-CCUUUAAAUUCCCAAAGGGUU-3 ¶; and antisense, 5 ¶-CCCUUUGGGAAUUUAAAGGAA-3 ¶. Human choroidal or retinal endothelial cells were grown to at least 80% confluence in 6 or 10 cm diameter dishes and subsequently incubated for 24 hours with UCHL1 or nontargeted siRNA in complex with Targefect-siRNA transfection kit reagents (Targeting Systems, El Cajon, Calif ) in accordance with the manufacturer's instructions. After transfection, the endothelial cells were rested at 37-C in modified MCDB-131 medium with 5% FBS for 24 hours, ahead of use in cell proliferation or cell migration assays. For every cell proliferation or cell migration assay, protein was extracted from parallel, identically transfected cultures of human choroidal or retinal endothelial cells and was interrogated using Western blot using rabbit polyclonal antihuman UCHL1 antibody (Cedarlane Laboratories) and mouse monoclonal antihuman A-actin antibody (clone AC-15, isotype IgG1; Sigma-Aldrich) to verify UCHL1 protein knockdown.
Cell Proliferation Assay
Transfected human choroidal or retinal endothelial cells were plated in 96-well plates at 6 Â 10 3 or 9 Â 10 3 cells per well and subsequently incubated at 37-C in modified MCDB-131 medium with 5% FBS. After 48 hours, cell proliferation was measured using the CyQuant NF Cell Proliferation Assay Kit (Molecular Probes; Life Technologies). Instructions of the manufacturer were followed exactly with the exception that the volume of dye-binding solution applied to each well was 50 KL. Fluorescence intensity was measured on a microplate reader (VICTOR 3 Multilabel Counter 1420; PerkinElmer Life, Waltham, Mass) at room temperature within 2 hours of equilibration of dye-DNA binding, with excitation set at 485 nm and emission detected at 530 nm.
Cell Migration Assay
Transfected human choroidal or retinal endothelial cells in modified MCDB-131 medium with 10% FBS (0.3 mL aliquots containing 7.5 Â 10 4 or 15 Â 10 4 cells) were added to polyethylene terephthalate transwells with 0.3 cm 2 diameter membranes that were pierced with 8-Km pores (BD Falcon, Franklin Lakes, NJ). The transwells were subsequently placed into wells of a 24-well plate, containing 1.2 mL of the same medium. After overnight incubation, the membranes were fixed with 4% paraformaldehyde, washed with phosphate-buffered saline, and air-dried. They were excised from the transwells and mounted on glass slides in ProLong Gold antifade reagent with DAPI (Molecular Probes; Life Technologies). Lower surfaces of the membranes were imaged under Â200 magnification at the confocal microscope (FluoView FV1000 confocal microscope; Olympus America, Center Valley, Pa). The number of migrated cells was averaged across 6 photographic fields for each membrane.
Statistical Methods
The data obtained in cell proliferation assays and cell migration assays were presented as mean T standard error of mean. The data from the 2 groups were compared by unpaired 2-tailed Student t test using GraphPad Prism (GraphPad Software, La Jolla, Calif ). A significant difference was defined as one yielding a P value of less than 0.05.
Ethics
The human tissue used in the reported work was purchased from the ''Lions VisionGift'' eye bank. Because the US Office for Human Research Protections does not consider the deceased to be human subjects, institutional review board clearance did not apply to this work.
RESULTS
Human Choroidal and Retinal Endothelial Cells Express Ubiquitin Carboxyl-Terminal Esterase L1 In Vivo
Reports that human endothelium expresses UCHL1 are based solely on studies with cultured endothelial cells. 10Y13 However, in vitro culture may impact cell phenotype, and thus, we examined UCHL1 expression in vivo using intact choroid and retina dissected from human cadaver eyes (Fig. 1) . In comparison with the tissue stained with control antibody, the tissue stained with specific antibody detected UCHL1 in choroidal endothelial cells (Figs. 1A, B ) and retinal endothelial cells (Figs. 1C, D) . There was some nonspecific uptake of the antibody within vessels. Consistent with the neuroscience literature, 7 positive staining was observed in the nerve fiber, ganglion cell, as well as inner and outer plexiform layers of the retina, and some staining also was noted in the choroidal stroma. These results confirm that human choroidal and retinal endothelial cells express UCHL1 in vivo.
Targeted Knockdown of Ubiquitin Carboxyl-Terminal Esterase L1 Consistently Inhibits Human Choroidal and Retinal Endothelial Cell Proliferation
Endothelial cell proliferation is one key process in neovascularization. We studied the effect of siRNA-mediated UCHL1 silencing on human retinal and choroidal endothelial cell proliferation using an assay in which cellular DNA was fluorescently tagged for quantification using a microplate reader (Fig. 2) . This assay does not evaluate cell viability. Ubiquitin carboxyl-terminal esterase L1Yspecific knockdown resulted in a significant reduction in mean cell proliferation by 18.1% to 59.5% for 6 of the 6 human choroidal or retinal endothelial isolates ( Figs. 2A, C) . Western blot of protein extracts from the siRNA-treated cells confirmed knockdown by specific siRNA (Figs. 2B, D) . This result suggests that UCHL1 may be involved in ocular endothelial cell proliferation in most persons.
Targeted Knockdown of Ubiquitin Carboxyl-Terminal Esterase L1 Variably Inhibits Human Choroidal and Retinal Endothelial Cell Migration
Endothelial cell migration is a second key process in neovascularization. We examined the impact of siRNA-mediated UCHL1 silencing on human retinal and choroidal endothelial cell migration, counting the number of endothelial cells moving across a perforated membrane (Fig. 3) . Ubiquitin carboxyl-terminal esterase L1Yspecific knockdown resulted in a significant reduction in cell migration for 2 of the 3 human choroidal endothelial isolates and 1 of the 3 human retinal endothelial isolates; where significant, mean migration was reduced by 36.3% to 76.6% (Figs. 3A, C) . Western blot of protein extracts from the siRNA-treated cells confirmed knockdown by specific siRNA (Figs. 3B, D) . This result suggests that UCHL1 also may be involved in ocular endothelial cell migration in some individuals.
DISCUSSION
Pharmacological inhibition of VEGF-A represents a major advance in the treatment of intraocular neovascularization. However, because this treatment approach is not effective in all cases and may cause toxicity to the intraocular tissues, there is interest in identifying additional regulators of neovascularization for therapeutic targeting. This study identifies UCHL1 as one such molecule. Ubiquitin carboxyl-terminal esterase L1 is generally considered a neuron-specific protein, 7 but our profiling work has identified expression of UCHL1 in cultured ocular endothelial cells 12, 13 and other groups have reported expression by human umbilical vein and aortic endothelial cells 10 as well as cells with the potential to differentiate into endothelial cells. 11 Applying immunohistochemistry to human choroid and retina, we provide the important in vivo confirmation of these previous cell culture studies, which have suggested that UCHL1 is synthesized by human endothelial cells. This is the first report to implicate UCHL1 in neovascularization within the eye or in any body location. Evidence in the scientific literature suggested that UCHL1 might influence blood vessel growth. Human choroidal endothelial sprouting is potently inhibited by the proteasome inhibitor, epoxomicin. 18 Because UCHL1 is a deubiquitinating enzyme, this result suggests that UCHL1 might inhibit neovascularization. On the other hand, work in cancer biology indicates that UCHL1 counteracts von Hippel-Lindau tumor-suppressor proteinYchaperoned ubiquitination of HIF-1>. 14 This should promote vessel growth by stabilizing HIF-1>, which activates transcription of VEGF-A. Indeed, using targeted siRNA to reduce cellular expression of UCHL1 in cultured cells, we show that UCHL1 promotes the proliferation and migration of human choroidal and retinal endothelial cells; UCHL1-specific knockdown resulted in significantly less proliferation and migration for 6 of the 6 and 3 of the 6 human choroidal or retinal endothelial cell isolates, respectively. This suggests that, in the human eye, choroidal and retinal endothelial UCHL1 promotes neovascularization.
One strength of our work is its use of human cells and tissues. Information on endothelial cell involvement in intraocular neovascular disease derives largely from work conducted in mice. Mice provide important in vivo models, but the structure of the mouse eye and its circulation differ from those of the human, and scale disparities of multiple parameters likely result in differences in the level of oxygenation of cells and effects on vessel proliferation in disease. 19 Studies focusing on basic disease processes that involve human ocular endothelial cells therefore have unique value, although models are necessarily in vitro. Our results from experiments using multiple human isolates highlight an important issue in working in a human system. We observed UCHL1 involvement in endothelial proliferation for all 6 isolates, but in endothelial migration, we observed UCHL1 involvement for only half of the isolates. Although technical variation, including variation in the level of UCHL1 knockdown achieved by targeted siRNA, likely contributes to differences between results, gene expression varies across humans. Indeed, our previous work shows that gene expression profiles of choroidal and retinal endothelial cells from different human donors are distinct. 12 Research is often based on cells derived from a single human donor. These data show the importance of studying multiple donors when investigating the role of human endothelial cells in disease.
Potential for toxicity to neurons is a concern in specifically targeting UCHL1, given the role of UCHL1 in axonal transport.
It is possible to target blockade to the proliferating ocular endothelial cells that contribute to neovascularization and limit off-target expression in retinal neurons and nondividing ocular vascular endothelial cells. For example, this could be achieved using UCHL1-specific siRNA, transcribed under control of a human Cdc6 promoter-multimerized mouse endothelinYenhancer element, delivered by lentiviral construct. Cdc6 promotes the cell transition from resting to active division. The multimerized endothelin enhancer stimulates promoter activity within endothelial cells. Originally described by Szymanski et al, 20 this promoterenhancer element achieves high and exclusive expression of reporter and therapeutic transgenes within proliferating endothelial cells in the mouse eye. 21 In summary, our study indicates that UCHL1 is expressed by human choroidal and retinal endothelial cells in vivo and suggests that UCHL1 may be involved in ocular endothelial proliferation in most persons and in ocular endothelial migration in some persons. The data support a hypothesis that UCHL1 promotes choroidal and retinal neovascularization and suggest that UCHL1 may be a suitable target of a new treatment for neovascular eye disease. Studies using in vivo models, including laser-induced choroidal neovascularisation and oxygen-induced retinopathy in the mouse, 22 would be an appropriate follow-up investigation, ahead of clinical application.
